EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quinazolin-4-one/3-cyanopyridin-2-one Hybrids as Dual Inhibitors of EGFR and BRAFV600E: Design, Synthesis, and Antiproliferative Activity

Lamya H Al-Wahaibi, Mohamed Hisham iD, Hesham A Abou-Zied iD, Heba A Hassan, Bahaa G M Youssif, Stefan Bräse iD, Alaa M Hayallah iD, Mohamed Abdel-Aziz

Pharmaceuticals · 26.10.2023 · 16 (11) · 1522

DOI: 10.3390/ph16111522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 26.10.2023. Verfasst von Lamya H Al-Wahaibi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Sciences, Princess Nourah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel series of hybrid compounds comprising quinazolin-4-one and 3-cyanopyridin-2-one structures has been developed, with dual inhibitory actions on both EGFR and BRAFV600E. These hybrid compounds were tested in vitro against four different cancer cell lines. Compounds 8, 9, 18, and 19 inhibited cell proliferation significantly in the four cancer cells, with GI50 values ranging from 1.20 to 1.80 µM when compared to Doxorubicin (GI50 = 1.10 µM). Within this group of hybrids, compounds 18 and 19 exhibited substantial inhibition of EGFR and BRAFV600E. Molecular docking investigations provided confirmation that compounds 18 and 19 possess the capability to inhibit EGFR and BRAFV600E. Moreover, computational ADMET prediction indicated that most of the newly synthesized hybrids have low toxicity and minimal side effects.

Schlagwörter

Stichwörter der Autor:innen

3-cyanopyridin-2-oneBRAFV600EEGFRanti-cancerdockingquinazolin-4-one

Autor:innen und Institutionen

  • Department of Chemistry, College of Sciences, Princess Nourah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia.
  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Universities Zone, New Minia City 61111, Egypt.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
  • Institute of Biological and Chemical Systems, IBCS-FMS, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Sphinx University, Assiut 71515, Egypt.

ORCID-Profile: Mohamed Hisham, Hesham A Abou-Zied, Stefan Bräse, Alaa M Hayallah

Förderung

  • Princess Nourah bint Abdulrahman University

Zitieren

APA

Al-Wahaibi, L. H., Hisham, M., Abou-Zied, H. A., Hassan, H. A., Youssif, B. G. M., Bräse, S., Hayallah, A. M., & Abdel-Aziz, M. (2023). Quinazolin-4-one/3-cyanopyridin-2-one Hybrids as Dual Inhibitors of EGFR and BRAFV600E: Design, Synthesis, and Antiproliferative Activity. Pharmaceuticals, 16(11), 1522. https://doi.org/10.3390/ph16111522

Vancouver

Al-Wahaibi LH, Hisham M, Abou-Zied HA, Hassan HA, Youssif BGM, Bräse S, et al. Quinazolin-4-one/3-cyanopyridin-2-one Hybrids as Dual Inhibitors of EGFR and BRAFV600E: Design, Synthesis, and Antiproliferative Activity. Pharmaceuticals. 2023;16(11):1522. doi:10.3390/ph16111522

BibTeX
@article{AlWahaibi2023,
  author = {Al-Wahaibi, Lamya H and Hisham, Mohamed and Abou-Zied, Hesham A and Hassan, Heba A and Youssif, Bahaa G M and Bräse, Stefan and Hayallah, Alaa M and Abdel-Aziz, Mohamed},
  title = {Quinazolin-4-one/3-cyanopyridin-2-one Hybrids as Dual Inhibitors of EGFR and BRAFV600E: Design, Synthesis, and Antiproliferative Activity},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {11},
  pages = {1522},
  doi = {10.3390/ph16111522}
}
Kostenlos starten →